Federal Government Announces Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional) Grant Funding
U.S. Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases announces the availability of funding for implementation of the Next Generation Multipurpose Prevention Technologies (NGM) (R01 Clinical Trial Optional) Grant. The purpose of this grant is to support the continued development of new and innovative on-demand, event-driven, and long-acting (systemic and non-systemic) multipurpose prevention technologies (MPTs). It supports development of MPTs that prevent HIV infection and pregnancy (hormonal and non-hormonal methods); sexually transmitted infections (STI) and pregnancy; or multiple non-HIV STI or HIV/STI MPTs . . .